198 related articles for article (PubMed ID: 32636452)
1. Histopathologic features of breast cancer in Li-Fraumeni syndrome.
Kuba MG; Lester SC; Bowman T; Stokes SM; Taneja KL; Garber JE; Dillon DA
Mod Pathol; 2021 Mar; 34(3):542-548. PubMed ID: 32636452
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.
Masciari S; Dillon DA; Rath M; Robson M; Weitzel JN; Balmana J; Gruber SB; Ford JM; Euhus D; Lebensohn A; Telli M; Pochebit SM; Lypas G; Garber JE
Breast Cancer Res Treat; 2012 Jun; 133(3):1125-30. PubMed ID: 22392042
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
[TBL] [Abstract][Full Text] [Related]
4. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
5. Uncovering the genomic heterogeneity of multifocal breast cancer.
Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
[TBL] [Abstract][Full Text] [Related]
6. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
8. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
[TBL] [Abstract][Full Text] [Related]
10. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
11. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
[TBL] [Abstract][Full Text] [Related]
13. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
Dabbs DJ; Chivukula M; Carter G; Bhargava R
Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
[TBL] [Abstract][Full Text] [Related]
14. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
15. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
16. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
17. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
18. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
[TBL] [Abstract][Full Text] [Related]
19. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
20. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.
Herbert BS; Chanoux RA; Liu Y; Baenziger PH; Goswami CP; McClintick JN; Edenberg HJ; Pennington RE; Lipkin SM; Kopelovich L
Oncotarget; 2010 Oct; 1(6):405-422. PubMed ID: 21311097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]